Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ACTRN12626000077369) titled 'Zoledronate Early Administration to Limit rebound bone loss' on Jan. 20.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Primary Sponsor: Western Sydney Local Health District
Condition:
osteoporosis
osteoporosis
Musculoskeletal - Osteoporosis
Intervention:
Zoledronic acid 5 mg Intravenous infusion over ~30 minutes (100 mL solution) by a research nurse.
First dose 3 months after the participant's last denosumab injection
Recruitment Status: Not Recruiting
Phase: Phase 4
Date of First Enrollment: 02/02/2026
Target Sample Size: 36
Countries of Rec...